Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Health-Related Legislation

July 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

S5755, an amendment (no. 603) introduced by Sen. McConnell (R-KY), to reform the health-care liability system and improve health-care quality through establishment of quality assurance programs, was agreed to by voice vote.

  • S5755, an amendment (no. 603) introduced by Sen. McConnell(R-KY), to reform the health-care liability system and improvehealth-care quality through establishment of quality assuranceprograms, was agreed to by voice vote.
  • S5793, an amendment (no. 605) introduced by Sen. Wellstone(D-MN), to revise provisions regarding reports on medical malpracticedata and access to certain information, was tabled by voice vote.
  • S5800, an amendment (no. 608) introduced by Sen. Snowe (R-ME),to limit the amount of punitive damages that may be awarded ina health-care liability action, was agreed to by voice vote.
  • S5931, an amendment (no. 611) introduced by Sen. Kyl (R-AZ),to place a limitation of $500,000 on noneconomic damages thatare awarded to compensate a claimant for pain, suffering, emotionaldistress, and other related injuries, was tabled by voice vote.
  • H1566, a bill to amend the Internal Revenue Code to make permanentthe credit for clinical testing expenses for certain drugs andrare diseases or conditions was introduced by Rep. Johnson (R-CT).
Articles in this issue

ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection
House Panel Holds Hearing on Self-Referral
Health-Related Legislation
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
Responses to Anti-HER2 MoAb Seen
NCI Committed to Increasing Minority Participation in Clinical Trials

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Related Content

Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

Roman Fabbricatore
August 22nd 2025
Article

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 22nd 2025
Podcast

The developer submitted their request in writing and anticipates a response from the FDA before the end of Q3 2025.

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tim Cortese
August 22nd 2025
Article

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 22nd 2025
Podcast

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 22nd 2025
Article

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 22nd 2025
Article
Related Content

Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

Roman Fabbricatore
August 22nd 2025
Article

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 22nd 2025
Podcast

The developer submitted their request in writing and anticipates a response from the FDA before the end of Q3 2025.

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tim Cortese
August 22nd 2025
Article

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 22nd 2025
Podcast

Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population

Roman Fabbricatore
August 22nd 2025
Article

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 22nd 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.